The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

In a stable market, experience is an asset. But in a disruptive industry like today's biotech, experienced leaders may rely on outdated playbooks. First-time executives can be more valuable because they approach problems from first principles, unburdened by past successes that are no longer relevant.

Dr. Vibha Jawa's career shows a powerful strategy: learning drug development fundamentals in large companies (Amgen, Merck) and applying them in nimble startups. This cycle across different environments accelerates learning and deepens expertise in a specialized field like immunogenicity.

When moving to a new industry, even as an experienced engineer, expect to start at the bottom. Embracing a "beginner's mindset" to learn the new domain's specific applications of fundamental principles is key to proving your value and succeeding in a new environment.

Many academics incorrectly assume an industry job is a simple fallback if their academic career fails. This mindset leads them to underestimate the different skill sets required, often resulting in poor interview performance because they lack practical coding abilities and view the opportunity as a personal failure.

The core job of a scientist isn't knowing facts, but figuring out what's unknown. This problem-solving 'toolbox'—how to think, act, and work with teams to tackle new problems—is directly transferable to the CEO role, enabling leaders to navigate unfamiliar domains like corporate finance or legal structures.

Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.

The difference between successful and unsuccessful drug hunters isn't intelligence or education, but cultural attributes that exist 'in the margin.' These include radical transparency, honesty, humility, and being part of a supportive, truth-seeking team. These soft skills determine the outcome of high-stakes R&D.

Infinimmune's hiring process prioritizes 'judgment under uncertainty' by actively screening for people who are comfortable admitting the limits of their expertise. Wyatt McDonnell believes a team member who is confidently wrong is far more destructive to a high-stakes project than one who can honestly identify their knowledge gaps.